• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cassava Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    12/23/25 8:46:03 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAVA alert in real time by email
    sava20251222_8k.htm
    false 0001069530 0001069530 2025-12-19 2025-12-19
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     
     

     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): December 19, 2025
     
     

     
     
    Cassava Sciences, Inc.
    (Exact name of registrant as specified in its charter)
     
     

     
    Delaware
    001-41905
    91-1911336
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
     
    6801 N Capital of Texas Highway, Building 1; Suite 300
    Austin, Texas 78731
    (Address of Principal Executive Offices) (Zip Code)
     
    (512) 501-2444
    (Registrant's telephone number, including area code)
     
     
    (Former name or former address, if changed since last report)
     
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.001 par value
    SAVA
    NASDAQ Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 1.01 Entry into a Material Definitive Agreement.
     
    Background
    Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. These actions were filed in the U.S. District Court for the Western District of Texas (the “Texas District Court”). The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company's securities. On June 30, 2022, a federal judge consolidated the four class action lawsuits into one case (the “Consolidated Securities Action”) and appointed a lead plaintiff and a lead counsel. Pursuant to Local Rule CV-88(g) governing Alternative Dispute Resolution (“ADR”), the parties to the Consolidated Securities Action engaged in mediation with David M. Murphy of Phillips Alternative Dispute Resolutions Enterprises (the “Mediator”).
     
    Settlement Term Sheet Summary
    On December 19, 2025, at the direction of the Mediator, plaintiffs in the Consolidated Securities Action (“Plaintiffs”) filed a Final ADR Report with the Texas District Court as required by Local Rule CV-88(g). As stated in the Final ADR Report, defendants Cassava and Eric J. Schoen (the “Cassava Defendants”) and Plaintiffs have accepted a double-blind Mediator’s Recommendation, reflected in a binding term sheet (the “Term Sheet”) pursuant to which the Cassava Defendants will pay Plaintiffs $31.25 million to achieve a complete settlement of all claims and causes of action that have been or could be asserted by Plaintiffs in exchange for full and complete releases. The Final ADR Report further states that, although defendants Remi Barbier and Lindsay Burns (the “Non-Settling Defendants”), did not execute the Term Sheet, those individuals are indemnified by Cassava and under the Term Sheet are entitled to receive full and complete releases along with Cassava upon final approval of a settlement by the Texas District Court.
     
    As the Term Sheet has been interpreted by the Mediator, the Term Sheet now constitutes a complete and enforceable settlement agreement of Cassava Defendants and the class, which is defined as all purchasers or acquirers of Company common stock or call options on Company common stock or sellers of put options on Company common stock between September 14, 2020 and October 12, 2023 (subject to certain exclusions), inclusive (the “Class Period”) in respect of the Consolidated Securities Action.
     
    The Mediator determined that it is for the Texas District Court to resolve the question whether later-filed securities class action litigation should be consolidated in the Consolidated Securities Action.
     
    The Term Sheet provides that the Company will pay a settlement amount equal to $31.25 million, which is expected to be placed into escrow in January 2026. In exchange, the Plaintiffs and the class will grant full and complete releases in favor of the Cassava Defendants and the Non-Settling Defendants of all of their claims that were or could have been asserted in the Consolidated Securities Action and will dismiss with prejudice the claims asserted against the Non-Settling Defendants. The settlement is not an admission of fault or wrongdoing by the Company.
     
    The Company reserved a loss contingency of $31.25 million in the second quarter of 2025 relating to the Consolidated Securities Action.
     
    The Cassava Defendants and Plaintiffs intend to prepare a formal stipulation of settlement and motion for preliminary approval of the settlement describing the terms of the proposed settlement, which will be presented to the Texas District Court for preliminary approval. Following preliminary approval of the proposed settlement by the Texas District Court and a notice and review period for class members, Plaintiffs will seek final approval of the proposed settlement from the Texas District Court.
     
     

     
     
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Cassava Sciences, Inc.
     
     
    a Delaware corporation
     
           
           
    Date: December 23, 2025
    By:
    /s/ Eric J. Schoen
     
       
    Eric J. Schoen
     
       
    Chief Financial Officer
     
           
     
     
    Get the next $SAVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAVA

    DatePrice TargetRatingAnalyst
    11/26/2024Buy → Neutral
    H.C. Wainwright
    10/8/2024$116.00Neutral → Buy
    H.C. Wainwright
    7/1/2024Buy → Neutral
    H.C. Wainwright
    11/16/2022$44.00Buy → Neutral
    B. Riley Securities
    1/24/2022$108.00 → $72.00Buy
    B. Riley Securities
    7/20/2021$97.00 → $124.00Buy
    HC Wainwright & Co.
    7/15/2021$100.00Overweight → Neutral
    Cantor Fitzgerald
    7/7/2021$80.00 → $190.00Buy
    Maxim Group
    More analyst ratings

    $SAVA
    SEC Filings

    View All

    Cassava Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    12/23/25 8:46:03 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 8-K/A filed by Cassava Sciences Inc.

    8-K/A - CASSAVA SCIENCES INC (0001069530) (Filer)

    12/22/25 4:09:39 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Other Events

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    12/18/25 5:02:27 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/20/25 5:39:26 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/20/25 5:39:26 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    11/26/24 7:44:43 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00

    10/8/24 8:06:57 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    7/1/24 7:48:24 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

    AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management's participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City. Rick Barry, President and Chief Executive Officer, will participate in-person at this corporate event. Conference details are as follows: H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Corporate PresentationDate: Monday, S

    8/25/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

    AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,

    10/22/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Reports Q2 2025 Financials Results and Provides Business Update

    Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c

    8/14/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/13/24 5:01:04 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/1/24 4:00:47 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Financials

    Live finance-specific insights

    View All

    Cassava Sciences to Hold Corporate Update on November 25th

    AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.    Event Details:    Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: https://lifescievents.com/event/cassava/    A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnolog

    11/24/24 8:01:09 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

    AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.   Event details:  Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy   A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

    10/31/24 8:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

    AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

    8/1/24 8:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care